

**P&T Motion History**  
**Biologic Drugs for Asthma and Urticaria, Biologics for Non-asthma Conditions**

Drugs reviewed	Motion	Date reviewed	Surveillance accepted as adequate	Reiteration of prior motion	Decision
dupilumab mepolizumab omalizumab	<p><b>Biologics for non-asthma conditions:</b>            After considering the evidence of safety, efficacy and special populations for the treatment of their FDA approved indications excluding asthma, I move that dupilumab, mepolizumab, omalizumab are safe and efficacious for the treatment of their approved indications. Dupilumab, mepolizumab, omalizumab can be subject to therapeutic interchange in the Washington preferred drug list for their FDA approved indications excluding asthma.</p> <p>Motion: Flatebo            2<sup>nd</sup>: Chawla</p>	February 16, 2022	NA	No	Passed unanimous
benralizumab <b>dupilumab*</b> mepolizumab omalizumab reslizumab	<p><b>Biologics for Asthma and Urticaria:</b>            After considering the evidence of safety, efficacy and special populations for the treatment of asthma and chronic spontaneous urticaria, I move that benralizumab, dupilumab, mepolizumab, omalizumab, and reslizumab are safe and efficacious for the treatment of their approved indications. Benralizumab, dupilumab, mepolizumab, and reslizumab can be subject to therapeutic interchange in the Washington preferred drug list for asthma and chronic spontaneous urticaria.</p> <p>Motion: Park            2<sup>nd</sup>: Buccola</p>	April 21, 2021	NA	No	Passed unanimous

**Bold** = new this update

Grey\* = Categorized under Atopic Dermatitis on WA PDL

4/6/2021